Caesarstone Ltd. filed a Report of Foreign Private Issuer on November 3, 2026, disclosing an agenda change to its 2026 Annual General Meeting scheduled for November 25, 2026, substituting Dr. Ariel Halperin for Mr. Aviv Ben Horin as a director candidate following a qualifying shareholder request.

Key Highlights

  • Agenda revision: Dr. Ariel Halperin's re-election was added to the 2026 Annual General Meeting agenda after a shareholder holding sufficient voting rights submitted a request under the Israeli Companies Law.
  • Candidacy withdrawal: Mr. Aviv Ben Horin withdrew his candidacy, and Proposal No. 6 was revised to remove him from the ballot.
  • Proposal updates: Proposal No. 1 was revised for Dr. Halperin's re-election, and Proposal No. 5 was revised to include Dr. Halperin among directors to receive option grants.
  • Dates unchanged: The Meeting date of November 25, 2026, the notice date of October 21, 2026, and the record date of October 20, 2026 all remain in effect.
  • Compensation disclosure: Related disclosures were revised to address the continuation of Dr. Halperin's compensation under the Management Agreement.
  • Signed by CFO: The report was signed by Nahum Trost, Chief Financial Officer of Caesarstone Ltd.

Caesarstone Revises AGM Proposals After Shareholder-Driven Director Change

According to the filing, Caesarstone Ltd., an Israel-based manufacturer of engineered quartz surfaces traded on NASDAQ:CSTE, issued an updated proxy statement for its 2026 Annual General Meeting after a qualifying shareholder exercised rights under Section 66(b) of the Israeli Companies Law, 5759-1999, and the Israeli Companies Regulations (Notice and Announcement of a General Meeting and a Class Meeting in a Public Company and the Addition of an Item to the Agenda), 5760-2000. The shareholder request required the Board of Directors to add the re-election of Dr. Ariel Halperin as a director to the meeting agenda.

The company disclosed that three specific proposals were affected by the change. Proposal No. 1 was revised to provide for Dr. Halperin's re-election in place of Mr. Ben Horin's candidacy. Proposal No. 5 was revised to include Dr. Halperin among the directors designated to receive option grants. Proposal No. 6 was revised to remove Mr. Ben Horin entirely. The filing also noted that related disclosures concerning the composition of the Board following the Meeting, as well as the continuation of Dr. Halperin's compensation under the Management Agreement, were updated to conform to his candidacy.

The filing stated that under the Companies Law and the Notice Regulations, the addition of an agenda item pursuant to a shareholder request does not affect the date of the original meeting notice or the record date. As a result, the company confirmed that the notice date of October 21, 2026, and the record date of October 20, 2026, remain "unchanged and in full force and effect." Updated proxy materials, including a revised notice and proxy statement (Exhibit 99.1) and an updated proxy card (Exhibit 99.2), were furnished with the filing. The report is incorporated by reference into the company's Registration Statements on Form S-8 under file numbers 333-180313, 333-210444, 333-251642, and 333-295843.

What Was Disclosed

Caesarstone Ltd. furnished an updated proxy statement on November 3, 2026, disclosing the substitution of Dr. Ariel Halperin for Mr. Aviv Ben Horin on the 2026 Annual General Meeting agenda, with no change to the meeting date, notice date, or record date.